Talphera (TLPH) Stock Analysis & AI Equity Report
Talphera (TLPH) overview
Talphera (TLPH) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.0m and operating profit of USD -13.5m; the year-end share price was 1.14 USD and market capitalisation was USD 56.2m. Talphera is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Talphera's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Talphera
Talphera is a specialty pharmaceutical company developing therapies for medically supervised settings. Its portfolio centers on Niyad, a nafamostat formulation under study as a regional anticoagulant for the extracorporeal circuit during continuous renal replacement therapy in hospitalized patients. The company is also exploring LTX-608, a nafamostat formulation for intravenous infusion, for potential use in several acute conditions.
Generate the Talphera report
Talphera is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Talphera and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Talphera
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.